Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$5.20 USD
-0.25 (-4.59%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.30 +0.10 (1.92%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Humacyte, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 2 | 1 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 2 | 1 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 100 | 86 | 82 | 0 | 0 |
Income After Depreciation & Amortization | -100 | -85 | -81 | 0 | 0 |
Non-Operating Income | -4 | 79 | 59 | 0 | NA |
Interest Expense | 7 | 6 | 4 | 0 | NA |
Pretax Income | -111 | -12 | -26 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -111 | -12 | -26 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -111 | -12 | -26 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -92 | -75 | -72 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 8 | 10 | 9 | 0 | NA |
Income After Depreciation & Amortization | -100 | -85 | -81 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 103.42 | 103.05 | 39.97 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.93 | -0.86 | -2.06 | NA | NA |
Diluted Net EPS (GAAP) | -1.07 | -0.12 | -0.66 | -0.08 | NA |
Fiscal Year end for Humacyte, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 29.50 | 26.57 | 26.18 | 24.62 | 26.73 |
Income After SG&A, R&D, and Dept/Amort Expenses | -29.50 | -26.57 | -26.18 | -24.62 | -26.73 |
Non-Operating Income | -24.65 | -3.50 | 2.80 | 0.09 | 5.74 |
Interest Expense | 2.52 | 1.82 | 1.73 | 1.46 | 1.71 |
Pretax Income | -56.66 | -31.90 | -25.11 | -26.00 | -22.71 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -56.66 | -31.90 | -25.11 | -26.00 | -22.71 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -56.66 | -31.90 | -25.11 | -26.00 | -22.71 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 119.18 | 108.25 | 103.61 | 103.44 | 103.36 |
Diluted EPS Before Non-Recurring Items | -0.27 | -0.29 | -0.24 | -0.25 | -0.22 |
Diluted Net EPS (GAAP) | -0.48 | -0.29 | -0.24 | -0.25 | -0.22 |